# Monteris Medical

> Monteris Medical makes NeuroBlate, an MRI-guided, robotically controlled laser ablation system used by neurosurgeons to destroy targeted brain tissue. Its hospital-focused platform combines cooled laser probes, thermal monitoring software and robotic positioning for selected patients with brain tumors, radiation necrosis or drug-resistant epilepsy.

- **Founded:** 1999
- **Headquarters:** Minnetonka, United States
- **Founders:** Mark G. Torchia (Co-founder; laser ablation researcher), Richard Tyc (Co-founder; Senior Vice President, Science and Technology)
- **Products:** NeuroBlate System, NeuroBlate Fusion-S Software, NB3 FullFire 1.6mm Laser Probe, FullFire and SideFire 3.3mm Laser Probes, Monteris Mini-Bolt
- **Notable:** FDA NeuroBlate clearance recorded April 1, 2013., Founders named 2020 Pioneer in Technology Award recipients by the Society for Brain Mapping & Therapeutics., More than 100 hospital installations reported in October 2022.

## Products & services

- **NeuroBlate System** — MRI-guided robotic laser platform for ablating intracranial soft tissue; combines hardware, software and disposable surgical components. FDA clearance for NeuroBlate recorded April 1, 2013.
- **NeuroBlate Fusion-S Software** — Planning and thermal visualization software; commercial release and FDA clearance announced July 2020.
- **NB3 FullFire 1.6mm Laser Probe** — Cooled, adjustable-length diffusing probe; commercial release announced May 1, 2024.
- **FullFire and SideFire 3.3mm Laser Probes** — Diffuse and directional energy delivery options for different ablation geometries.
- **Monteris Mini-Bolt** — Cranial access component that interfaces with NeuroBlate robotic probe positioning.

## Achievements

- FDA NeuroBlate clearance recorded April 1, 2013.
- Founders named 2020 Pioneer in Technology Award recipients by the Society for Brain Mapping & Therapeutics.
- More than 100 hospital installations reported in October 2022.
- 2025 JAMA Neurology publication analyzed 145 patients with drug-resistant mesial temporal lobe epilepsy.
- August 2026 announcement described a prospective oncology dataset of 787 patients at 25 US centers.

## Latest updates

- **2026-08** — Announced Journal of Clinical Oncology publication covering 787 brain tumor patients from LAANTERN.
- **2026-03** — Closed US$28 million Series E and established a separate US$35 million Trinity Capital credit facility.
- **2026-01** — Announced TRICARE coverage for LITT following advocacy with military and veteran organizations.
- **2025-10** — Announced Symphony Robotics micro-robotics development collaboration.

## Links

- Website: https://www.monteris.com/
- LinkedIn: https://www.linkedin.com/company/monteris-medical/
- Twitter/X: https://twitter.com/MonterisMed
- Facebook: https://www.facebook.com/MonterisMedical/

---

Profile page: https://yespress.io/monteris-medical
Published by YesPress — https://yespress.io
Last updated: 2026-10-15